OSIR - Osiris Therapeutics, Inc. - Page 3

Hmm they sold 1.76 million shares.... On June 6th for financing.

got in at 13.86 yesterday, last minute spike, closed over 14 resistance, we'll see if that continues today

broke out

Hang on tight the miltary just awarded a contract close to their market cap. Halted now. Will run like the wind when they let her lose. Congrats to all you longs. You hit pay dirt.

Press ReleaseSource: Osiris Therapeutics

Osiris Therapeutics Awarded Department of Defense Contract for Prochymal(TM) Fully Valued at $224.7 Million
Thursday January 3, 5:22 pm ET
First award granted under Osiris - Genzyme partnership is aimed at protecting U.S. military from the lethal effects of acute radiation syndrome

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics (Nasdaq:OSIR - News) announced today that it has been awarded a $224.7 million contract, including purchase options, from the United States Department of Defense (DoD) to develop and stockpile Prochymal, an adult stem cell therapy, for the repair of gastrointestinal injury resulting from radiation exposure.

story goes on @ yahoo

I was looking to get in below 12. but that news hit, oh well. Now I'm looking for it under 13. This seems to be the first stem stock to get a nice pop in 2008.

I've been accumulating STEM, ASTM, and CUR lately. I don't know why more people aren't all over them yet...but that's okay

I love a nice, quiet opportunity

Just made a nice daily longtail hammer at support. I'd get in this Monday at least for a swing but I think OSIR is going to new highs over the next few months. Obama will most likely win, then stem cell industry will be on fire.

Tuesday, September 8, 2009, 9:35am EDT | Modified: Tuesday, September 8, 2009, 10:14am
Osiris suffers another stem cell setback
Washington Business Journal - by Tucker Echols Staff Reporter

Osiris Therapeutics Inc. suffered another setback for plans to commercialize its stem cell drug Prochymal, as the drug proved no better than a placebo in two final trials.

Columbia, Md.-based Osiris Tuesday said preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease showed no statistical difference between the drug and a placebo in either trial. Osiris said Prochymal did show significant improvements in response rates in difficult-to-treat liver and gastrointestinal graft versus host disease even as it failed to meet its primary endpoint in both trials.

Osiris investors were unhinged by the news and sent shares of Osiris down as much as 40 percent. Osiris stock (NASDAQ:OSIR) declined $4.89 to $7.32 at the opening bell of Tuesday trading. The shares then recovered modestly and were down $4.21 to $8 each as of 9:49 a.m.

Graft versus host disease is the most common complication of bone marrow transplantation, and is a life-threatening disease for which there is currently no approved treatment.

“These data are still preliminary and further analysis is needed to gain a full appreciation of the results of these rigorous, double-blind, placebo-controlled trials,” said Osiris CEO C. Randal Mills. “We are encouraged to see Prochymal significantly improve response rates above standard of care in graft versus host disease patients who currently have no good treatment options,” Mills said. “We will meet with the FDA as soon as possible to discuss the most appropriate and efficient path forward.”

The trial failure is the third disappointing result for a Prochymal test this year. In March, the company halted enrollment in a final stage trial of Prochymal as a treatment for Crohn’s disease after noting significantly higher than expected placebo response rates. And in June, Osiris said that a test of Prochymal as a treatment for patients with lung disease showed that the drug significantly decreased inflammation, but did not significantly improve pulmonary function six months into the two-year trial.

Prochymal is a mixture of mesenchymal stem cells made into an intravenous injection. The mesenchymal stem cells used in Prochymal are harvested from the bone marrow of healthy young adult donors and then grown in culture.

According to Osiris, studies suggest mesenchymal stem cells are able to facilitate tissue repair by reducing severe inflammation and working at the cellular level to rebuild damaged tissue through the release of tissue specific growth factors.

bouncing 7.54. some possible short covering here soon

From the chart, this one is coming back from the death
The last few days has been on the upside.
It just needs to pick up the pace (volume).
Any thought?

Chart is starting to look good from what I can see. Trading above 50day MA, and MACD is crossing. I'm just learning charts, so if someone can please shed some insight I would appreciate it.
Thanks

watch for breakout 8.30

COLUMBIA, Md. (AP) -- Shares of stem cell therapy developer Osiris Therapeutics Inc. jumped Friday after the company reported a smaller-than-expected loss in the first quarter.

Osiris said it lost $1.3 million, or 4 cents per share, in the first three months of the year. In the first quarter of 2011 the company reported a profit of $4 million, or 12 cents per share. It said its research and development costs shrank to $4 million from $4.7 million. Revenue fell to $3.4 million from $10.4 million.

Analysts expected a loss of 9 cents per share and $3.4 million in revenue, according to FactSet.

Osiris is studying a stem cell therapy called Prochymal, which is aimed at treating graft vs. host disease, a side effect of organ or bone marrow transplants. Its Chondrogen therapy is designed to treat osteoarthritis of the knee. The company also sells biosurgery products that are designed to promote healing, and it said revenue from those products rose 49 percent to $1.1 million.

Osiris was developing Prochymal and Chondrogen as part of a partnership with Genzyme, a unit of French drugmaker Sanofi. In late 2008 Genzyme agreed to pay Osiris $130 million upfront to start the partnership, and Osiris' revenue in the first quarter of 2011 included a $10 million portion of that payment.

However in February Sanofi said it discontinued late-stage testing of Prochymal. Osiris said it believes Sanofi has terminated the collaboration and that it should regain all rights to Prochymal. Osiris said Sanofi disagrees and the companies are discussing their status.

Shares of Osiris Therapeutics jumped 39 cents, or 7.9 percent, to close at $5.30.

nice channel play for a while now...